



# Late Effects of Cancer Treatment and Survivorship:

## Strategies for Primary Care and Oncology Care Providers

### CONTINUING MEDICAL EDUCATION PROGRAM

**Now Available Online!**

#### To Access the Online Program

Go to:  
<http://www.bluecrosscalifornia.cecity.com>

Login and click on the program  
under Featured CME Programs.

#### Powered by:



#### Tuition

There is no tuition for  
participating in this activity.

#### Course Director

##### Patricia A. Ganz, MD

Professor  
David Geffen School of Medicine at  
UCLA  
UCLA School of Public Health  
Jonsson Comprehensive Cancer  
Center  
Los Angeles, California

##### Lisa Diller, MD

Medical Director  
Perini Family Survivors' Center  
Dana-Farber Cancer Institute  
Clinical Director of Pediatric Oncology  
Dana-Farber Cancer Institute and  
Children's Hospital  
Boston, Massachusetts

##### Betty Ferrell, RN, PhD, FAAN

Research Scientist  
City of Hope National Medical Center  
Duarte, California

Late Effects of Cancer Treatment and  
Survivorship: Strategies for Primary  
Care and Oncology Care Providers is  
supported in part by educational  
grants from the following: American  
Cancer Society; Amgen Inc.;

**Release Date: September 1, 2006**

**Expiration Date: September 1, 2007**

**Estimated time to complete activity: 3.0 hours**

#### Target Audience

This program is designed to meet the educational needs of primary care and oncology care physicians and nurses who care for individuals with cancer or who have survived cancer.

#### Program Goals

This educational program has been designed to promote provider understanding regarding late effects of cancer treatment and survivorship and their role in long-term surveillance in order to reduce adverse health outcomes of cancer survivors.

#### Educational Objectives

After completing this activity, the participant should be better able to:

- Describe national trends and information related to late effects of cancer treatment and survivorship for pediatric and adult populations.
- Assess survivorship medical and psychosocial issues.
- Recognize providers' role/opportunity in monitoring and managing pediatric and adult patients' late effects.
- Understand long-term follow-up guidelines that provide recommendations for screening and management of late effects that may potentially arise as a result of therapeutic exposures used during cancer.
- Manage strategies/issues surrounding transition of care to primary care after discharge from cancer treatment.
- Understand the importance of communication between primary care and oncology care providers and potential barriers such as socioeconomic disparities.

#### Accreditation

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA designates this educational activity for a maximum of 3 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AstraZeneca; Blue Cross of California; Bristol-Myers Squibb Company; Genentech, Inc.; John Wayne Cancer Foundation; Lance Armstrong Foundation; Merck and Co., Inc.; Pharmion Corporation; Sanofi-Aventis; and the WellPoint Foundation. This activity is endorsed by the Northern California Cancer Center.

This activity is brought to you by the Office of Continuing Medical Education, David Geffen School of Medicine at UCLA in conjunction with Blue Cross of California, an independent licensee of the Blue Cross Association.



## Continuing Education for Nurses

In California, Category 1 Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course has been taken within the appropriate time frames. When completing the renewal form or the online CE section, under the section labeled "Provider Number," you will need to enter CME Category 1, instead of a BRN Provider Number.

## Disclosure of Conflicts of Interest

The FDA has issued a concept paper that classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is "truly independent" and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program's participants. In addition, Accreditation Council for Continuing Medical Education policy now mandates that the provider adequately manages all identified potential conflicts of interest prior to the program. We at UCLA fully endorse the letter and spirit of these concepts.

# DYNAMIC CME

A PRODUCT OF WELLPOINT PHARMACY MANAGEMENT



SETTING THE BENCHMARK TODAY, FOR THE CME PROGRAMS OF TOMORROW



## Welcome to DynamicCME!

Our mission is to create the most advanced technological solutions to help our providers meet their educational needs.

[Click here to login](#)



## DISCOVER

Click any of the buttons below to find out more.

**WHAT**  
is **DYNAMICCME**

**WHY**  
use **DYNAMICCME**

**LEARN**  
about **DYNAMICCME**

\*ADOBE ACROBAT REQUIRED



## CONTACT US

[Click here](#) to send us an email.

## KEY

Announcement  
**Blue Cross of California** welcomes  
all its providers to **DYNAMICCME!**



**CECITY** POWERED FOR OUR TERMS OF USE AND PRIVACY POLICY PLEASE REVIEW OUR [LEGAL AGREEMENT](#).  
COPYRIGHT CECITY.COM, INC. © 2005 ALL RIGHTS RESERVED.

Blue Cross of California and BC Life & Health Insurance Company are Independent licensees of the Blue Cross Association and are licensed to conduct business in the State of California.